futurhealth tirzepatide for Medical Weight Loss in Denver, CO FuturHealth | Let's set the

doi: 10.3389/fcdhc.2026.1772391 Received 20 December 2025 Revised 15 March 2026 Accepted 16 March 2026 Published 10 April 2026 Volume 7 - 2026 Edited by Arrigo Francesco Giuseppe Cicero, University of Bologna, Italy Reviewed by Alessando Mattina, IRRCS ISMETT/UPMC Italy, Italy Updates Copyright 2026 Jdrasek, Lisowska and Czupryniak

Integration into clinical practice will rely on forthcoming phase III data, cost-effectiveness analyses, and evolving guidelines

Skin that felt smooth in March starts to feel rough and uneven by July

More patients ( n [%]) switched to semaglutide OW from liraglutide than from dulaglutide (139 [84.8%] versus 25 [15.2%], respectively), and a total of 86 patients (52.4%) were on insulin therapy when they switched to semaglutide OW (Table 1)

Each of these compounds is a peptide-based agonist , but they differ in their receptor targeting and metabolic impact which translates to meaningful differences in fat loss outcomes, metabolic markers, and lean body mass preservation

DOI: 10.1038/nm.3145 Benvenga S, Ruggeri RM, Russo A, Lapa D, Campenni A, Trimarchi F